An increase in the discount rate suggests higher perceived risk or a higher cost of capital for the project, which lowers the asset's present value. A decrease indicates improved risk assessment or lower capital costs, increasing the asset's valuation.
The discount rate applied to the projected future cash flows of the HLD-0117 asset to determine its present value. This...
Comparable to weighted average cost of capital (WACC) or risk-adjusted hurdle rates used by pharmaceutical peers for specific clinical-stage pipeline assets.
jnj_segment_hld_0117_discount_rate| Q4 '25 | |
|---|---|
| Value | 0.2 |